WebSolithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. … WebAug 18, 2024 · Shigemura and his research team in Japan likewise reported that a deletion mutation of the mtrR promoter region is a possible mechanism of ... Golden M, Jamieson …
—Formal review of solithromycin by EMA now underway—
WebSolithromycin (trade name Solithera) is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia [1] and other infections. [2] … WebSolithromycin is predominantly metabolized and then excreted in the feces (approximately 77% of total radioactivity). Urinary excretion (14%) is a minor contributor to the overall graphing a slope intercept equation
Solithromycin for the treatment of drug-resistant gonorrhoea
WebIntroduction: Solithromycin is a novel fluoroketolide developed to treat pneumonia. But, few studies evaluating its antimicrobial activity against S. pneumoniae in a mixed-infection … WebMar 28, 2024 · Solithromycin is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in … WebA phase 3 CAP study utilizing a 7-day oral dosing regimen of solithromycin is currently enrolling in Japan (conducted by Toyama Chemical Co., Ltd., Tokyo) and will provide additional safety and efficacy data in adults with CAP. Solithromycin is also currently being evaluated in pediatric patients with CAP, aged 2 months to 17 years (NCT02605122). graphing a solution on a number line